Skip to content

Study · Not a test of the peptide alone · 2019

6 results

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM

Breast cancer research : BCR22 Jan 2019Cited by 53 (Europe PMC)

PMID30670061 (opens in a new tab)PMCIDPMC6343247 (opens in a new tab)DOI10.1186/s13058-018-1092-x (opens in a new tab)PepBankPUB-30670061
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

BackgroundImmunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death through the release of danger-associated molecular pattern molecules (DAMPs), LTX-315 is capable of reshaping the tumor microenvironment, turning "cold" tumors "hot" through a significant increase in tumor-infiltrating lymphocytes.MethodsWe investigated the potential of LTX-315 to be used in combination with standard-of-care chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1 mammary fat pad model. Tumor growth curves were compared using one-way ANOVA analysis of variance and Tukey's multiple comparisons test, and animal survival curves were compared using the log-rank (Mantel-Cox) test. We considered p values ≤0.05 to indicate statistical significance.ResultsWe found that LTX-315 displayed a strong additive antitumoral effect when used in combination with CAELYX®, and induced immune-mediated changes in the tumor microenvironment, followed by complete regression in the majority of animals treated. Furthermore, imaging techniques and histological examination showed that the combination induced strong local necrosis, followed by an increase in the infiltration of CD4+ and CD8+ immune cells into the tumor parenchymal tissue.ConclusionsOur data demonstrate that LTX-315 is a promising combination partner with CAELYX® for the treatment of triple-negative breast cancer.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

  1. 01AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome

    In an orthotopic mammary tumor model, LTX‑315 with CAELYX showed a strong additive antitumoral effect.

    In plain wordsIn animals, LTX‑315 with CAELYX showed a strong additive effect against mammary tumors.

    Peptide
    LTX-315
    Outcome
    DecreaseAdditive antitumoral effect
    Study

    n: not reported in source

    orthotopic 4 T1 mammary fat pad model
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    We found that LTX-315 displayed a strong additive antitumoral effect when used in combination with CAELYX®, and induced immune-mediated changes in the tumor microenvironment, followed by complete regression in the majority of animals treated.
    1 context sentence
    Summary · context
    We investigated the potential of LTX-315 to be used in combination with standard-of-care chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1 mammary fat pad model.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  2. 02AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In an orthotopic mammary tumor model, LTX‑315 with CAELYX induced immune-mediated changes in the tumor microenvironment.

    In plain wordsIn animals, LTX‑315 with CAELYX caused immune-mediated changes in the mammary tumor environment.

    Peptide
    LTX-315
    Outcome
    Not applicableTumor immune microenvironment changes
    Study

    n: not reported in source

    orthotopic 4 T1 mammary fat pad model
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    We found that LTX-315 displayed a strong additive antitumoral effect when used in combination with CAELYX®, and induced immune-mediated changes in the tumor microenvironment, followed by complete regression in the majority of animals treated.
    1 context sentence
    Summary · context
    We investigated the potential of LTX-315 to be used in combination with standard-of-care chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1 mammary fat pad model.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  3. 03AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome

    In an orthotopic mammary tumor model, LTX‑315 with CAELYX led to complete regression in most treated animals.

    In plain wordsIn animals, LTX‑315 with CAELYX led to complete mammary tumor regression in most treated animals.

    Peptide
    LTX-315
    Outcome
    DecreaseComplete tumor regression
    Study

    n: not reported in source

    orthotopic 4 T1 mammary fat pad model
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    We found that LTX-315 displayed a strong additive antitumoral effect when used in combination with CAELYX®, and induced immune-mediated changes in the tumor microenvironment, followed by complete regression in the majority of animals treated.
    1 context sentence
    Summary · context
    We investigated the potential of LTX-315 to be used in combination with standard-of-care chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1 mammary fat pad model.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  4. 04AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In an orthotopic mammary tumor model, LTX‑315 with CAELYX induced strong local necrosis.

    In plain wordsIn animals, LTX‑315 with CAELYX induced strong local mammary tumor necrosis.

    Peptide
    LTX-315
    Outcome
    IncreaseLocal necrosis
    Study

    n: not reported in source

    orthotopic 4 T1 mammary fat pad model
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Furthermore, imaging techniques and histological examination showed that the combination induced strong local necrosis, followed by an increase in the infiltration of CD4+ and CD8+ immune cells into the tumor parenchymal tissue.
    1 context sentence
    Summary · context
    We investigated the potential of LTX-315 to be used in combination with standard-of-care chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1 mammary fat pad model.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  5. 05AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In an orthotopic mammary tumor model, LTX‑315 with CAELYX increased CD4+ cell infiltration into tumor tissue.

    In plain wordsIn animals, LTX‑315 with CAELYX increased CD4+ immune cells in mammary tumor tissue.

    Peptide
    LTX-315
    Outcome
    IncreaseCD4+ cell infiltration
    Study

    n: not reported in source

    orthotopic 4 T1 mammary fat pad model
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    Furthermore, imaging techniques and histological examination showed that the combination induced strong local necrosis, followed by an increase in the infiltration of CD4+ and CD8+ immune cells into the tumor parenchymal tissue.
    1 context sentence
    Summary · context
    We investigated the potential of LTX-315 to be used in combination with standard-of-care chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1 mammary fat pad model.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  6. 06AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In an orthotopic mammary tumor model, LTX‑315 with CAELYX increased CD8+ cell infiltration into tumor tissue.

    In plain wordsIn animals, LTX‑315 with CAELYX increased CD8+ immune cells in mammary tumor tissue.

    Peptide
    LTX-315
    Outcome
    IncreaseCD8+ cell infiltration
    Study

    n: not reported in source

    orthotopic 4 T1 mammary fat pad model
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    Furthermore, imaging techniques and histological examination showed that the combination induced strong local necrosis, followed by an increase in the infiltration of CD4+ and CD8+ immune cells into the tumor parenchymal tissue.
    1 context sentence
    Summary · context
    We investigated the potential of LTX-315 to be used in combination with standard-of-care chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1 mammary fat pad model.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.